Drug Profile
Research programme: heart surgery therapeutics - PYC Therapeutics/Baker IDI
Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Baker Heart Research Institute; Phylogica
- Developer Baker IDI; PYC Therapeutics
- Class Peptide fragments
- Mechanism of Action Cell death inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ischaemic heart disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Ischaemic-heart-disorders in Australia (Parenteral)
- 19 Apr 2010 Early research is ongoing in Australia
- 26 Jul 2006 Early research in Ischaemic heart disorders in Australia (Parenteral)